Navigation Links
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
Date:9/9/2008

LAS VEGAS, Sept. 9 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) today announces that its first US site is open for patient enrollment for its Phase II clinical trial for the treatment of severe coronary heart disease. In the coming weeks, CVBT anticipates announcing additional sites as they open for enrollment. For current details about the clinical sites participating in CVBT's Phase II heart trial, please visit http://www.cvbt.com.

In this Phase II trial, CVBT's drug candidate containing human Fibroblast Growth Factor-1 (FGF-1), will be injected into patients' hearts, stimulating a healing process called angiogenesis. The drug will be delivered using the NOGA(R) XP Cardiac Navigation system and the MyoStar(TM) injection catheter.

Subjects must be between 25 and 75 years of age with at least a 3 month history of chronic stable angina triggered by physical exertion and must have a Canadian Cardiovascular Society (CCS) anginal classification III or IV while receiving optimal medical therapy. Their treating cardiologist will have determined that they are generally not suitable for interventional therapy or bypass surgery.

"Developing a clinical trial protocol such as ours takes an extraordinary amount of time and effort, and I am pleased to finally open our Phase II heart trial for patient screening," said Daniel C. Montano, CVBT's President and CEO. "I expect additional investigators at other hospitals to begin screening patients in the coming weeks. Our target is 30 hospitals for this international Phase II heart trial."

About CardioVascular BioTherapeutics

CVBT (OTC Bulletin Board: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the com
'/>"/>

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
2. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
5. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
6. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
7. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
10. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
11. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), a company ... and physician groups, today reported financial results for the ... "In the second quarter of 2015, Semler reported continued ... quarter over quarter revenue growth of 8%, and quarter ... units of 18%," said Doug Murphy-Chutorian, M.D., chief executive ...
(Date:7/31/2015)... India , July 31, 2015 ... CRM solutions for video, data and cloud computing ... with a leading pharma giant for Internet of ... different IoT applications offered on subscription model. ... Pharma giant is striving for business innovations ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 /PRNewswire/ ... that it will release its second quarter 2015 financial ... 6, 2015.   In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... BETHESDA, Md., May 14 Spherix Incorporated (Nasdaq: ... for diabetes therapy, and a provider of technical ... and pharmaceutical companies, today announced that, on May ... new, independent Director, Thomas B. Peter, to begin ...
... in ACR20 responses over placeboPRINCETON, N.J., May 14 ... today announced that the MDX-1100 Phase 2 proof-of-concept ... receiving methotrexate successfully met its primary endpoint. The ... randomized, double-blind, placebo-controlled Phase 2 trial indicated that ...
Cached Medicine Technology:Spherix Elects New Independent Director, and Elects Chairman of the Board 2Spherix Elects New Independent Director, and Elects Chairman of the Board 3Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 2Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 3Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 4
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, ... are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) ... well as tried-and-true products that have stood the test of time. These include ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
Breaking Medicine News(10 mins):Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- Nicotine patches ... women quit smoking, a new study finds. Dr. Tim ... University of Nottingham in England, and colleagues assigned 1,050 women ... two groups. Members of one group received behavioral smoking cessation ...
... substantial amount of trans fats are more likely than their ... However, the risk of stroke associated with trans ... the findings from University of North Carolina at Chapel Hill ... Ischemic Stroke Among Postmenopausal Women," was published Thursday (March 1, ...
... the severe symptoms of a life-threatening bone marrow cancer called ... according to a phase III clinical trial published in the ... . "The Phase I/II clinical trial showed that ruxolitinib ... now this phase III study indicates that the drug extends ...
... Many leading causes of death are linked to ... in minority populations have lower levels of physical ... to the Department of Health & Human Services. ... found that minority adults who received exercise interventions ...
... (HealthDay News) -- Children with a depressed father are more ... Most prior research has focused on depressed mothers and ... to the researchers from the NYU School of Medicine. ... households. About 25 percent of kids whose mother and father ...
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- Patients who ... are less likely to develop depression than those not on ... Dr. Mary Whooley of the San Francisco VA Medical ... patients for depression. The researchers found those taking statins were ...
Cached Medicine News:Health News:Nicotine Patches May Not Help During Pregnancy 2Health News:Nicotine Patches May Not Help During Pregnancy 3Health News:Aspirin may counteract potential trans fat-related stroke risk in older women 2Health News:Drug improves survival and quality of life for people with myelofibrosis 2Health News:Drug improves survival and quality of life for people with myelofibrosis 3Health News:Fitness programs for minority adults lack cultural relevance, MU study finds 2Health News:Dad's Depression May Rub Off on Child's Behavior 2Health News:Could a Statin Lower Your Risk for Depression? 2Health News:Could a Statin Lower Your Risk for Depression? 3
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Optimal solution for normal acetabulum and younger patients....
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
Medicine Products: